Veronica Gil
YOU?
Author Swipe
View article: MON-555 PPARγ Genetic Variant c 1169del. A Not So Common Case of Induced Insulin Resistance
MON-555 PPARγ Genetic Variant c 1169del. A Not So Common Case of Induced Insulin Resistance Open
Disclosure: A. Contreras-Arce: None. A. Pechir-Cerrillo: None. V. De la Pena Gil: None. C. Castillo-Castro: None. P. Portillo-Sanchez: None. Introduction: Insulin resistance is a complex disorder associated with the development of metaboli…
View article: Figure 5 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Figure 5 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
NXP800-resistant 22Rv1 prostate cancer cell sublines demonstrate the reversal of the NXP800-mediated phenotype. A, Long-term treatment of 22Rv1 prostate cancer cells with increasing concentrations (up to 2.5 μmol/L) of DMSO (vehicle-C, whi…
View article: Figure 1 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Figure 1 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
GO cellular response to heat gene expression signature associates with AR signaling and poorer prognosis in men suffering from CRPC. A and G, Two independent (PCF-SU2C and ICR-RMH) transcriptome cohorts of patients with CRPC. Quantificatio…
View article: Figure 3 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Figure 3 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
NXP800 inhibits the growth of AR-dependent and AR-independent prostate cancer models with activation of the UPR and inhibition of key signaling pathways. A and B, PDX-O [CP50, CP89, CP129, and CP142 (A)], AR-positive (VCaP, LNCaP, LNCaP95,…
View article: Supplementary Figure S6 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Supplementary Figure S6 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
Supplementary figure 6: Inhibition of the unfolded protein response with ISRIB rescues NXP800-mediated suppression of AR signaling and PCa model growth
View article: Figure 2 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Figure 2 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
NXP800 inhibits AR transactivation and AR signaling to inhibit the growth of AR aberrant prostate cancer models. A–C, VCaP (A), LNCaP95 (B), and 22Rv1 (C) prostate cancer cells were treated with vehicle (DMSO 0.1%) or various concentration…
View article: Supplementary Figure S2 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Supplementary Figure S2 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
Supplementary figure 2: AR and AR-V7 bind members of the 70KDa heat shock protein family and heat shock mediated cellular stress increases HSP72 and AR-V7 protein expression, and associates with GO Cellular Response to Heat gene expression…
View article: Figure 6 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Figure 6 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
NXP800 activates the UPR and inhibits E2F-mediated transcription to drive antitumor activity against the castration-resistant VCaP prostate cancer cell line–derived mouse xenograft. A and B, Castration-resistant emergent VCaP prostate canc…
View article: Supplementary Figure S4 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Supplementary Figure S4 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
Supplementary figure 4: NXP800 decreases basal HSP72 protein levels and blocks HSP72 protein induction in response to HSP90 inhibition in PCa cell lines
View article: Supplementary Figure S10 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Supplementary Figure S10 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
Supplementary figure 10: NXP800 demonstrates limited impact on AR and AR-V7 protein levels and associated AR signaling in-vivo but does induce apoptosis and reduce cellular proliferation
View article: Supplementary Figure S8 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Supplementary Figure S8 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
Supplementary figure 8: NXP800 does not further impact AR transactivation or AR signaling in NXP800-resistant 22Rv1 PCa cell sub-lines.
View article: Supplementary Figure S5 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Supplementary Figure S5 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
Supplementary figure 5: Enzalutamide inhibits AR signaling in enzalutamide responsive VCaP PCa cells but not enzalutamide resistant LNCaP95 and 22Rv1 PCa cells.
View article: Supplementary Figure S3 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Supplementary Figure S3 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
Supplementary figure 3: GO Cellular Response to Heat gene expression signature associates with AR signaling in CRPC transcriptomes
View article: Data from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Data from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
Purpose:Advanced prostate cancer is invariably fatal, with the androgen receptor (AR) being a major therapeutic target. AR signaling inhibitors have improved overall survival for men with advanced prostate cancer, but treatment resistance …
View article: Supplementary Tables S1-S13 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Supplementary Tables S1-S13 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
Supplementary Tables
View article: Supplementary Figure S9 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Supplementary Figure S9 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
Supplementary figure 9: NXP800 demonstrates tolerability in a castration-resistant VCaP PCa cell line-derived mouse xenograft
View article: Supplementary Figure S1 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Supplementary Figure S1 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
Supplementary figure 1: Chemical structures of NXP800 and CCT365248
View article: Figure 4 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Figure 4 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
NXP800 activates the UPR and inhibits key signaling pathways identifying a novel mechanism of action in prostate cancer models. A, VCaP, LNCaP95, and 22Rv1 prostate cancer cells were treated with 250 nmol/L CCT365248 (inactive) or 250 nmol…
View article: Supplementary Figure S7 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
Supplementary Figure S7 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
Supplementary figure 7: NXP800 does not decrease basal HSP72 protein levels and HSP90 inhibitor-induced HSP72 protein induction in NXP800-resistant 22Rv1 PCa cell sub-lines
View article: NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth Open
Purpose: Advanced prostate cancer is invariably fatal, with the androgen receptor (AR) being a major therapeutic target. AR signaling inhibitors have improved overall survival for men with advanced prostate cancer, but treatment resistance…
View article: Data from HER3 Is an Actionable Target in Advanced Prostate Cancer
Data from HER3 Is an Actionable Target in Advanced Prostate Cancer Open
It has been recognized for decades that ERBB signaling is important in prostate cancer, but targeting ERBB receptors as a therapeutic strategy for prostate cancer has been ineffective clinically. However, we show here that membranous HER3 …
View article: Figure S2 from HER3 Is an Actionable Target in Advanced Prostate Cancer
Figure S2 from HER3 Is an Actionable Target in Advanced Prostate Cancer Open
Supplementary Figure S2
View article: Supplementary Data from HER3 Is an Actionable Target in Advanced Prostate Cancer
Supplementary Data from HER3 Is an Actionable Target in Advanced Prostate Cancer Open
Supplementary methods and Supplementary figure legends - Tracked Changes
View article: Figure S2 from HER3 Is an Actionable Target in Advanced Prostate Cancer
Figure S2 from HER3 Is an Actionable Target in Advanced Prostate Cancer Open
Supplementary Figure S2
View article: Figure S5 from HER3 Is an Actionable Target in Advanced Prostate Cancer
Figure S5 from HER3 Is an Actionable Target in Advanced Prostate Cancer Open
Supplementary Figure S5
View article: Supplementary Data from HER3 Is an Actionable Target in Advanced Prostate Cancer
Supplementary Data from HER3 Is an Actionable Target in Advanced Prostate Cancer Open
Supplementary methods and Supplementary figure legends - Tracked Changes
View article: Figure S1 from HER3 Is an Actionable Target in Advanced Prostate Cancer
Figure S1 from HER3 Is an Actionable Target in Advanced Prostate Cancer Open
Supplementary Figure S1
View article: Figure S3 from HER3 Is an Actionable Target in Advanced Prostate Cancer
Figure S3 from HER3 Is an Actionable Target in Advanced Prostate Cancer Open
Supplementary Figure S3
View article: Data from HER3 Is an Actionable Target in Advanced Prostate Cancer
Data from HER3 Is an Actionable Target in Advanced Prostate Cancer Open
It has been recognized for decades that ERBB signaling is important in prostate cancer, but targeting ERBB receptors as a therapeutic strategy for prostate cancer has been ineffective clinically. However, we show here that membranous HER3 …
View article: Figure S5 from HER3 Is an Actionable Target in Advanced Prostate Cancer
Figure S5 from HER3 Is an Actionable Target in Advanced Prostate Cancer Open
Supplementary Figure S5